|
04 Dec 2019 |
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
|
|
03 Dec 2019 |
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
|
|
26 Nov 2019 |
La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
|
|
26 Nov 2019 |
Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines
|
|
21 Nov 2019 |
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
|
|
21 Nov 2019 |
Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock
|
|
19 Nov 2019 |
BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury
|
|
13 Nov 2019 |
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors
|
|
11 Nov 2019 |
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
|
|
10 Nov 2019 |
Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
|
|
09 Nov 2019 |
Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
|
|
09 Nov 2019 |
Codiak Presents New Preclinical Data for First-in-Class Exosome Therapeutic Candidates, exoIL-12 and exoSTING, Demonstrating Potent Anti-Tumor Activity
|
|
08 Nov 2019 |
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
|
|
07 Nov 2019 |
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
|
|
06 Nov 2019 |
BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients
|
|
05 Nov 2019 |
Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
|
|
05 Nov 2019 |
Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)
|
|
04 Nov 2019 |
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint
|
|
01 Nov 2019 |
Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome
|
|
31 Oct 2019 |
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
|
|
31 Oct 2019 |
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
|
|
30 Oct 2019 |
TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction
|
|
28 Oct 2019 |
Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)
|
|
28 Oct 2019 |
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
|
|
26 Oct 2019 |
VISEN Pharmaceuticals announces China Phase 3 clinical study initiation for TransCon human growth hormone, the first unmodified long-acting growth hormone in China
|
